The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 16, 2023

Filed:

Dec. 08, 2016
Applicant:

Memorial Sloan Kettering Cancer Center, New York, NY (US);

Inventor:

Prasad S. Adusumilli, New York, NY (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); C07K 14/725 (2006.01); C07K 14/705 (2006.01); C12N 5/0783 (2010.01); A61P 37/06 (2006.01); A61K 9/00 (2006.01); A61K 38/17 (2006.01); A61K 39/395 (2006.01); C07K 16/30 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61K 9/0019 (2013.01); A61K 38/177 (2013.01); A61K 38/1774 (2013.01); A61K 39/39558 (2013.01); A61P 37/06 (2018.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 16/3069 (2013.01); C12N 5/0637 (2013.01); A61K 2039/505 (2013.01); C07K 2319/00 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C12N 2501/505 (2013.01); C12N 2501/51 (2013.01); C12N 2501/515 (2013.01); C12N 2501/599 (2013.01); C12N 2510/00 (2013.01);
Abstract

Disclosed herein are cells that are immunoinhibitory cell, which cells recombinantly express a dominant negative form of an inhibitor of a cell-mediated immune response of the cell. In certain embodiments, the immunoinhibitory cell is a regulatory T cell. In another aspect, provided herein is a regulatory T cell that recombinantly expresses a dominant negative form of an inhibitor of a regulatory T cell-mediated immune response. The cells can be sensitized to an antigen that is the target of a pathologic immune response associated with an immune-mediated disorder. Additionally provided are methods of using such cells to treat an immune-mediated disorder in a subject in need thereof.


Find Patent Forward Citations

Loading…